Peregrine Capital Management LLC acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 748,487 shares of the medical instruments supplier’s stock, valued at approximately $12,133,000. Peregrine Capital Management LLC owned approximately 2.04% of AngioDynamics at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of ANGO. Dimensional Fund Advisors LP increased its stake in AngioDynamics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,128,777 shares of the medical instruments supplier’s stock worth $54,285,000 after buying an additional 14,823 shares in the last quarter. Vanguard Group Inc. increased its stake in AngioDynamics by 7.4% in the first quarter. Vanguard Group Inc. now owns 1,694,290 shares of the medical instruments supplier’s stock worth $29,396,000 after buying an additional 116,814 shares in the last quarter. FMR LLC increased its stake in AngioDynamics by 1.8% in the fourth quarter. FMR LLC now owns 1,140,000 shares of the medical instruments supplier’s stock worth $19,232,000 after buying an additional 20,000 shares in the last quarter. Royce & Associates LP increased its stake in AngioDynamics by 18.7% in the first quarter. Royce & Associates LP now owns 810,312 shares of the medical instruments supplier’s stock worth $14,059,000 after buying an additional 127,764 shares in the last quarter. Finally, State Street Corp increased its stake in AngioDynamics by 21.4% in the fourth quarter. State Street Corp now owns 801,613 shares of the medical instruments supplier’s stock worth $13,518,000 after buying an additional 141,424 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.
AngioDynamics, Inc. (NASDAQ:ANGO) traded down 0.63% during mid-day trading on Friday, reaching $15.65. 325,430 shares of the company’s stock were exchanged. AngioDynamics, Inc. has a 52-week low of $14.80 and a 52-week high of $18.18. The company has a 50-day moving average of $15.88 and a 200-day moving average of $16.23. The stock’s market cap is $575.61 million.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The company had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. During the same period last year, the business earned $0.19 earnings per share. AngioDynamics’s revenue was down 7.0% compared to the same quarter last year. Equities research analysts anticipate that AngioDynamics, Inc. will post $0.67 earnings per share for the current year.
ANGO has been the subject of a number of recent research reports. Zacks Investment Research raised shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Wednesday, March 29th. Barclays PLC cut their price objective on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Wednesday. Canaccord Genuity reissued a “hold” rating and issued a $17.50 price objective on shares of AngioDynamics in a report on Thursday, March 30th. Cantor Fitzgerald boosted their price objective on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Finally, Craig Hallum set a $20.00 price objective on shares of AngioDynamics and gave the company a “buy” rating in a report on Saturday, April 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $18.50.
In related news, CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was acquired at an average cost of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,355,722.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Clemmer bought 5,000 shares of the company’s stock in a transaction on Friday, July 21st. The shares were bought at an average price of $15.79 per share, with a total value of $78,950.00. Following the completion of the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The disclosure for this purchase can be found here. 1.88% of the stock is currently owned by company insiders.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
